WO2002074948A3 - Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine - Google Patents

Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine Download PDF

Info

Publication number
WO2002074948A3
WO2002074948A3 PCT/CA2002/000378 CA0200378W WO02074948A3 WO 2002074948 A3 WO2002074948 A3 WO 2002074948A3 CA 0200378 W CA0200378 W CA 0200378W WO 02074948 A3 WO02074948 A3 WO 02074948A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
converted
animal tissue
carbohydrate antigens
compatible
Prior art date
Application number
PCT/CA2002/000378
Other languages
English (en)
Other versions
WO2002074948A2 (fr
Inventor
Chris Denning
A John Clark
J Michael Schiff
Original Assignee
Geron Corp
Chris Denning
A John Clark
J Michael Schiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp, Chris Denning, A John Clark, J Michael Schiff filed Critical Geron Corp
Priority to AU2002242538A priority Critical patent/AU2002242538B2/en
Priority to EP02708083A priority patent/EP1373498A2/fr
Publication of WO2002074948A2 publication Critical patent/WO2002074948A2/fr
Publication of WO2002074948A3 publication Critical patent/WO2002074948A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un système visant à produire un tissu animal comportant des antigènes carbohydrates compatibles en vue d'une greffe sur des patients humains. Le tissu est inactivé de manière homozygote pour l'expression d'α(1,3)galactosyltransférase, et comporte un transgène d'α(1,2)fucosyltransférase. Par conséquent, la N-acétyl lactosamine de surface ne se transforme pas en xéno-antigène Galα(1,3)Gal, mais en Fucα(1,2)Gal, qui constitue un antigène H, un auto-antigène chez l'être humain. Le tissu peut aussi contenir de la A ou B transférase, qui provoque la transformation d'antigène H en antigènes d'un autre groupe sanguin ABO de manière à assurer une compatibilité avec des patients du même type sanguin. L'invention permet d'améliorer la compatibilité de tissu de xénogreffe en réduisant le risque de réactions dues à des déterminants de xéno-antigènes et d'accepteurs de N-acétyl lactosamine non transformés.
PCT/CA2002/000378 2001-03-21 2002-03-21 Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine WO2002074948A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002242538A AU2002242538B2 (en) 2001-03-21 2002-03-21 Animal tissue with carbohydrate antigens compatible for human transplantation
EP02708083A EP1373498A2 (fr) 2001-03-21 2002-03-21 Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27781101P 2001-03-21 2001-03-21
US60/277,811 2001-03-21

Publications (2)

Publication Number Publication Date
WO2002074948A2 WO2002074948A2 (fr) 2002-09-26
WO2002074948A3 true WO2002074948A3 (fr) 2002-11-14

Family

ID=23062451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000378 WO2002074948A2 (fr) 2001-03-21 2002-03-21 Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine

Country Status (3)

Country Link
EP (1) EP1373498A2 (fr)
AU (1) AU2002242538B2 (fr)
WO (1) WO2002074948A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033831B2 (en) 2001-12-07 2006-04-25 Geron Corporation Islet cells from human embryonic stem cells
PT2163614T (pt) * 2002-08-21 2017-01-17 Revivicor Inc Animais porcinos que carecem de qualquer expressão de alfa 1,3 galactosiltransferase funcional
WO2005009134A1 (fr) 2003-07-21 2005-02-03 Lifecell Corporation Matrices de tissus acellulaires realisees a partir de tissus deficitaires en galactose $g(a)-1,3-galactose-
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
EP3799893A1 (fr) 2013-11-04 2021-04-07 LifeCell Corporation Procédé d'élimination d'alpha-galactose

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028412A1 (fr) * 1994-04-13 1995-10-26 Biotransplant, Inc. PORC NEGATIF POUR L'α(1,3) GALACTOSYLTRANFERASE
WO1995034202A1 (fr) * 1994-06-15 1995-12-21 Alexion Pharmaceuticals, Inc. Procedes permettant de reduire le rejet suraigu d'heterogreffes
WO1996028967A1 (fr) * 1995-03-17 1996-09-26 Chihiro Koike Mammiferes transgeniques autres que des primates, ou des serotypes de primates superieurs ont ete exprimes par un transfert de genes etrangers et procede pour creer ceux-ci
WO2000046355A2 (fr) * 1999-02-04 2000-08-10 Geron Corporation Sequences de regulation transcriptionnelle de la transcriptase inverse de la telomerase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028412A1 (fr) * 1994-04-13 1995-10-26 Biotransplant, Inc. PORC NEGATIF POUR L'α(1,3) GALACTOSYLTRANFERASE
WO1995034202A1 (fr) * 1994-06-15 1995-12-21 Alexion Pharmaceuticals, Inc. Procedes permettant de reduire le rejet suraigu d'heterogreffes
WO1996028967A1 (fr) * 1995-03-17 1996-09-26 Chihiro Koike Mammiferes transgeniques autres que des primates, ou des serotypes de primates superieurs ont ete exprimes par un transfert de genes etrangers et procede pour creer ceux-ci
WO2000046355A2 (fr) * 1999-02-04 2000-08-10 Geron Corporation Sequences de regulation transcriptionnelle de la transcriptase inverse de la telomerase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN CHAO-GUANG ET AL: "Reduction in Gal-alpha-1,3-Gal epitope expression in transgenic mice expressing human H-transferase.", XENOTRANSPLANTATION, vol. 3, no. 1 PART 2, 1996, pages 69 - 75, XP000909895, ISSN: 0908-665X *
SHINKEL T A ET AL: "CHANGES IN CELL SURFACE GLYCOSYLATION IN ALPHA1,3-GALACTOSYLTRANSFER ASE KNOCKOUT AND ALPHA1,2-FUCOSYLTRANSFERASE TRANSGENIC MICE", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 64, no. 2, 27 July 1997 (1997-07-27), pages 197 - 204, XP002922202, ISSN: 0041-1337 *
SUMIYAMA KENTA ET AL: "Gene diversity of chimpanzee ABO blood group genes elucidated from exon 7 sequences.", GENE (AMSTERDAM), vol. 259, no. 1-2, 2000, pages 75 - 79, XP002206147, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
AU2002242538B2 (en) 2007-06-28
EP1373498A2 (fr) 2004-01-02
WO2002074948A2 (fr) 2002-09-26

Similar Documents

Publication Publication Date Title
Kawahara et al. Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells
Barrett Understanding and harnessing the graft‐versus‐leukaemia effect
Setiady et al. In vivo depletion of CD4+ FOXP3+ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes
Tonti et al. NKT-cell help to B lymphocytes can occur independently of cognate interaction
Roux et al. Xenotransfusions, past and present
Galili Discovery of the natural anti‐Gal antibody and its past and future relevance to medicine
SE9600233D0 (sv) Antibakteriell komposition mot helicobacter
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
Bonam et al. Plasmodium falciparum malaria vaccines and vaccine adjuvants
DE69533964D1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
AU2001270408A1 (en) Intervertebral disc
BR0016973A (pt) Composição alimentìcia de animais domésticos para tratamento de espécies de helicobacter em animais domésticos
Galili Induced anti-non gal antibodies in human xenograft recipients
Galili Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?
Artrip et al. Target cell susceptibility to lysis by human natural killer cells is augmented by α (1, 3)-galactosyltransferase and reduced by α (1, 2)-fucosyltransferase
WO2002074948A3 (fr) Tissu animal comportant des antigenes carbohydrates compatibles en vue d'une greffe humaine
EP0700297A4 (fr) Tolerogenese de substitution destinee au developpement de la tolerance aux xenogreffes
WO2001091775A3 (fr) Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives
Galili Biosynthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) and their unique potential in future α-gal therapies
WO2000061766A3 (fr) Vaccin anticancereux specifique de la telomerase
Galili Paleo‐immunology of human anti‐carbohydrate antibodies preventing primate extinctions
Galili Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies
Saas et al. Intravenous apoptotic cell infusion as a cell‐based therapy toward improving hematopoietic cell transplantation outcome
Fucs et al. Frequency of natural regulatory CD4+ CD25+ T lymphocytes determines the outcome of tolerance across fully mismatched MHC barrier through linked recognition of self and allogeneic stimuli

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002708083

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002242538

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002708083

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002242538

Country of ref document: AU